Anales de la RANM

23 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 TRATAMIENTO NEOADYUVANTE DEL CÁNCER DE PULMÓN Mariano Provencio Pulla An RANM · Año 2019 · número 136 (01) · páginas 17 a 24 combination in the setting of neoadjuvant treatment in NSCLC but it is deemed not to reach the usual level of robustness needed to substantiate a new therapeutic indication due to the limitations previously outlined. To confirm these results a properly-designed and conducted randomized trial is mandatory to be able to address the limitations of the NADIM exploratory study and to generate a sound and sufficiently solid evidence of efficacy and safety and for that we will start NADIM II. ( Figure 2. NADIM II) We think that one of the most promising treatment modalities in stage III in lung cancer that has emerged in recent years is chemo-immunotherapy. 1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717. 2. López-Abente G, Pollán M, Aragonés N et al. Situación del cáncer en España: incidencia. An Sist Sanit Navar 2004; 27 (2): 165-173. 3. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008; 1: 5-13. 4. Hanna N, Neubauer M, Yiannoutsos et al. Phase III study of cisplatin, etoposide and concurrent chest radiation with or without consolidation with docetaxel in patients with inoperable stage III NSCLC: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26: 5755-5760. 5. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected satge IB-IIIA NSCLC (Adjuvant Navelbine International Trialist Association (ANITA): a randomised controlled trial. Lancet Oncol 2006; 7: 719-727. 6. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-3559. 7. Perez CA, Pajak TF, Rubin P et al. Long-term observations of the patterns of failure in patients with unresectable non oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group. Cancer 1987; 59: 1874–1881. 8. Langer CJ, Leighton JC, Comis RL et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): a phase II toxicity, response, and survival analysis (FCCC 93-024). J Clin Oncol 1995; 13: 1860-1870. 9. Non-Small Cell Lung Cancer Co-operative Group. Chemotherapy in non-small cell lung cancer: a meta- analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311: 899- 909. 10. Martin J, Ginsberg RJ, Ennapadam S et al. Long-term results of combined-modality therapy in resectable non- small cell lung cancer. J Clin Oncol 2002; 20: 1989-1995. 11. O´BrienMER, Splinter T, Smit EF et al. Carboplatin and paclitaxel (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer : an EORTC phase II study (EORTC 08958). Eur J Cancer 2003; 39: 1416-1422. 12. Zaragoulidis K, Kontakiotis T, Hatziapostolou P et al. A phase II study of docetaxel and carboplatin in the Figure 2. NADIM: Study design & Flow-chart BIBLIOGRAFÍA